Arch Therapeutics Inc. (ARTH) 0.2800 $ARTH
Arch Therapeutics Announces Private Placement
Marketwired - Wed Jul 01, 7:23AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM) ("AC5(TM)" , is pleased to announce that it raised $3,066,000 in equity financing in a private placement to 19 accredited investors (the "Investors" on June 30, 2015 (the "Initial Closing" , and anticipates raising up to an additional $100,000 before concluding the private placement (the "2015 Private Placement Financing" . At the Initial Closing, the Company sold and the Investors purchased 13,936,367 Units at a purchase price of $0.22 per Unit. Each Unit consisted of a share of the Company's common stock, par value $0.001 per share ("Common Stock" , and a Series D Warrant to purchase a share of Common Stock at an exercise price of $0.25 per share at any time prior to the fifth anniversary of the issuance date of the Series D Warrant. Upon raising the final $100,000 in expected financing, a total of 14,390,913 Units will have been issued in connection with the 2015 Private Placement Financing, and the number of outstanding shares of Common Stock will increase from 78,081,487 to 92,472,400.
The Cheapest Medical Device Stock I've Ever Seen
Michael Murphy, CFA - at Seeking Alpha - Fri Jun 26, 11:31AM CDT
JNJ: 99.53 (+1.13), MDCO: 32.73 (-0.24), BAX: 37.61 (+0.59)
Arch Therapeutics operating chief bids adieu
Seeking Alpha - at Seeking Alpha - Wed Jun 17, 3:27PM CDT
Arch Therapeutics Obtains Additional Safety Data for Its AC5 Surgical Hemostatic Device(TM) in Successful Preclinical Toxicity Test
Marketwired - Tue Jun 09, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM) ("AC5(TM)" , obtained data from a preclinical toxicity test for AC5(TM) that show the device was well-tolerated and classified as "not toxic" in a standardized test of systemic toxicity. The systemic toxicity animal test is a major component of the biocompatibility test panel that a medical device must typically complete successfully prior to use in humans. Testing was conducted under the guidelines provided by the International Organization for Standardization's (ISO) and the study also complied with Good Laboratory Practice (GLP), a Federal regulation (21 CFR part 58) governing the conduct of nonclinical laboratory studies that support or are intended to support applications for research or marketing permits for products regulated by the Food and Drug Administration (FDA). AC5 is a development-stage hemostasis product being evaluated to control bleeding and fluid loss in order to provide faster and better surgical and interventional care.
Arch Therapeutics Initiates Research and Development Collaboration With CURAM Centre for Research in Medical Devices
Marketwired - Mon Jun 01, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, executed a collaboration agreement with CURAM Centre for Research in Medical Devices, a new center of excellence for research based in Galway, Ireland that aims to radically improve health outcomes for patients by developing and collaborating on the development of "smart" medical devices.
Arch Therapeutics to Present at 2015 LD MICRO Invitational Conference on June 1
Marketwired - Mon May 18, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, will be featured as a presenting company at the LD MICRO Invitational conference on Monday, June 1, 2015 at 3:30 PM PDT. The conference will be held at the Luxe Sunset Hotel in Bel Air, California.
Global Wound Closure Devices Pipeline Review 2015
M2 - Tue Apr 28, 3:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/48sc22/wound_closure) has announced the addition of the "Wound Closure Devices - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key wound closure devices pipeline products. Scope: - Extensive coverage of the Wound Closure Devices products under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Wound Closure Devices and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry The report enables you to: - Formulate significant competitor information, analysis, and insights to improve R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of Wound Closure Devices under development - Develop market-entry and market expansion strategies - Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline - In-depth analysis of the product's current stage of development, territory and estimated launch date Companies Featured: - 3-D Matrix, Ltd. - Advanced Medical Solutions Group plc - Anika Therapeutics, Inc. - Arch Therapeutics Inc. - Arsenal Medical, Inc. - Baxter International Inc. - Bergen Medical Products, Inc. - Beth Israel Deaconess Medical Center, Inc. - Boston Scientific Corporation - Boston University - C. R. Bard, Inc. - Cellphire, Inc. - Clemson University - Emory University - Endomedix Incorporated - Entegrion, Inc. - Floralis S.A.S. - Johns Hopkins University - KeraNetics, LLC - Kitotech Medical, Inc. - Kuros Biosurgery AG - Laser Tissue Welding, Inc. - LifeBond Ltd. - Medical Adhesive Revolution GmbH - Medisse BV - Medtronic plc - OptMed, Inc. - Remedium Technologies Inc. - University of Akron - VitaThreads, LLC - Vivostat A/S - Vivostat A/S - Ongoing Clinical Trials Overview - Xcede Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/48...nd_closure
BSX: 17.60 (+0.15), MDT: 74.37 (+1.28), BAX: 37.61 (+0.59), ANIK: 33.33 (+0.31)
Arch Therapeutics' AC5(TM) Compared Favorably vs. Commercially Available Combination Hemostat in Animal Study
Marketwired - Thu Apr 16, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced that an independent third party has obtained favorable data from an animal study that compared the hemostatic activity of AC5 with a commercially available branded hemostat consisting of a flowable gelatin combined with thrombin.
Arch Therapeutics Announces Favorable Preclinical Data From an Independent Study of AC5 Surgical Hemostatic Device(TM) Versus a Popular Fibrin Sealant
Marketwired - Tue Apr 14, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced that an independent third party has obtained favorable data from a preclinical animal study that compared the hemostatic activity of AC5 with a popular and commercially available branded fibrin sealant that is indicated for use in controlling bleeding.
Arch Therapeutics Announces Favorable Preclinical Data from an Independent Study of AC5 Surgical Hemostatic Device(TM) Versus a Popular Cellulose-Based Hemostatic Agent
Marketwired - Wed Mar 25, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced that an independent third party has obtained favorable data from a preclinical animal study that compared the hemostatic activity of AC5 with a popular and commercially available branded absorbable hemostatic agent.
Arch Therapeutics Announces Positive Safety Results for AC5 Surgical Hemostatic Device(TM) in Preclinical Toxicity Studies
Marketwired - Mon Mar 23, 7:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, obtained additional favorable preclinical data from two (2) planned standardized medical device safety studies in which AC5 was assessed for toxicity to cells and for contamination from pyrogens (toxins that cause fever) produced by bacterial cells. The tests are major components of the panel of biocompatibility testing that medical devices must typically complete successfully prior to use in humans.
Nanomedicine: Nanotechnology, Biology, and Medicine Publishes Preclinical Data on Arch Therapeutics' AC5 Surgical Hemostatic Device(TM)
Marketwired - Thu Feb 19, 7:57AM CST
Positive data from an independent third-party research group study sponsored by Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), was published in the peer-reviewed journal Nanomedicine: Nanotechnology, Biology, and Medicine. The results in the manuscript, titled "AC5 Surgical Hemostat(TM) as an Effective Hemostatic Agent in an Anticoagulated Rat Liver Punch Biopsy Model," show that AC5(TM) is agnostic to the presence of the anticoagulant heparin in animals. The abstract can be accessed online here: http://www.nanomedjournal.com/article/S1549-9...8/abstract.
The British Standards Institution Classifies Arch Therapeutics' AC5(TM) as a Medical Device Within the European Union
Marketwired - Tue Feb 17, 7:03AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a medical device company and developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has received confirmation from The British Standards Institution (BSI), a Notified Body in the European Union (EU), that AC5 fulfills the definition of a medical device within the EU and will be classified as such in consideration for CE mark designation. Eventually obtaining the CE mark for AC5 would allow the Company to sell the product within the EU.
Arch Therapeutics Obtains Additional Positive Results for AC5 Surgical Hemostatic Device(TM) in Preclinical Safety Study
Marketwired - Tue Jan 13, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), obtained positive results when AC5(TM) was subjected to a standardized medical device test for irritation potential. The irritation test in animals is a major component of the International Organization for Standardization's (ISO) required panel of biocompatibility testing necessary for medical devices prior to use in humans. AC5 is a unique development-stage hemostasis product being evaluated to control bleeding and fluid loss in order to provide faster and safer surgical and interventional care.
Arch Therapeutics Announces Positive Results for AC5 Surgical Hemostatic Device(TM) in Biochemical and Cell Function Safety Studies
Marketwired - Tue Jan 06, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), obtained positive results from preclinical tests in which AC5(TM) was subjected to a battery of high-throughput in vitro safety assessments for biological interactions in standardized testing panels of receptors on the surface of cells and protein kinase enzymes inside cells. These receptors and enzymes represent important biochemical "switches," and interactions with them could indicate biological activity with the potential for toxicity. AC5 is a unique development-stage hemostasis product being evaluated to control bleeding and fluid loss in order to provide faster and safer surgical and interventional care.
Arch Therapeutics to Present at The Biotech Showcase(TM) 2015 Conference on January 14th 2015
Marketwired - Wed Dec 17, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), announced that it would be featured as a presenting company at The Biotech Showcase(TM) 2015 Conference on Wednesday, January 14, 2015 at 11:00 AM PST. The conference will be held at the Parc 55 Wyndham Hotel, located at Union Square, San Francisco, California.
ARTH Developing Next Generation Biopharma Product in a $5 Billion Market with Plans for Product Launch in 2015
M2 - Wed Dec 10, 7:13AM CST
ARTH's Flagship product AC5(TM) stops bleeding promptly, even in the presence of blood thinners based on animal data to date. Unlike many competitive products, it conforms to irregular wound geometry, allows for normal healing, and helps maintain a clear field of vision.
Arch Therapeutics to Present at LD Micro Main Event on December 4th 2014
Marketwired - Mon Nov 24, 3:00PM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), announced that it would be featured as a presenting company at the LD Micro conference on Thursday, December 4, 2014 at 12:00 PM EST. The conference will be held at the Luxe Sunset Hotel in Bel Air, California.
Arch Therapeutics Reports Positive Preclinical Data from Study of AC5 Surgical Hemostatic Device(TM) in Animals Treated with Brilinta(R) (ticagrelor)
Marketwired - Wed Nov 19, 3:26PM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostat Device(TM), announced that an independent third party has obtained positive data from a preclinical study assessing the use of AC5(TM) in animals that had been treated with orally administered therapeutic doses of the blood thinner ticagrelor, which is currently marketed under the brand name Brilinta(R). The results of the study are consistent with separate data obtained from two recently completed preclinical studies in which AC5 quickly stopped bleeding from surgical wounds created in rats following treatment with clinically relevant doses of the anticoagulant medication heparin; and another preclinical study which reported similar results with respect to the antiplatelet medications Plavix(R) (clopidogrel) and aspirin when used individually and in combination. Anticoagulant and antiplatelet medications are commonly referred to as "blood thinners."
Arch Therapeutics Will Present at Two Investor Conferences in November
Marketwired - Mon Nov 10, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), announced that it would be featured as a presenting company at two conferences in November: SeeThruEquity Microcap Investor Conference and Drexel Hamilton Micro-Cap Investor Forum.
Arch Therapeutics Announces Private Placement
Marketwired - Wed Jul 01, 7:23AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM) ("AC5(TM)" , is pleased to announce that it raised $3,066,000 in equity financing in a private placement to 19 accredited investors (the "Investors" on June 30, 2015 (the "Initial Closing" , and anticipates raising up to an additional $100,000 before concluding the private placement (the "2015 Private Placement Financing" . At the Initial Closing, the Company sold and the Investors purchased 13,936,367 Units at a purchase price of $0.22 per Unit. Each Unit consisted of a share of the Company's common stock, par value $0.001 per share ("Common Stock" , and a Series D Warrant to purchase a share of Common Stock at an exercise price of $0.25 per share at any time prior to the fifth anniversary of the issuance date of the Series D Warrant. Upon raising the final $100,000 in expected financing, a total of 14,390,913 Units will have been issued in connection with the 2015 Private Placement Financing, and the number of outstanding shares of Common Stock will increase from 78,081,487 to 92,472,400. The Cheapest Medical Device Stock I've Ever Seen
Michael Murphy, CFA - at Seeking Alpha - Fri Jun 26, 11:31AM CDT
JNJ: 99.53 (+1.13), MDCO: 32.73 (-0.24), BAX: 37.61 (+0.59)
Arch Therapeutics operating chief bids adieu
Seeking Alpha - at Seeking Alpha - Wed Jun 17, 3:27PM CDT
Arch Therapeutics Obtains Additional Safety Data for Its AC5 Surgical Hemostatic Device(TM) in Successful Preclinical Toxicity Test
Marketwired - Tue Jun 09, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM) ("AC5(TM)" , obtained data from a preclinical toxicity test for AC5(TM) that show the device was well-tolerated and classified as "not toxic" in a standardized test of systemic toxicity. The systemic toxicity animal test is a major component of the biocompatibility test panel that a medical device must typically complete successfully prior to use in humans. Testing was conducted under the guidelines provided by the International Organization for Standardization's (ISO) and the study also complied with Good Laboratory Practice (GLP), a Federal regulation (21 CFR part 58) governing the conduct of nonclinical laboratory studies that support or are intended to support applications for research or marketing permits for products regulated by the Food and Drug Administration (FDA). AC5 is a development-stage hemostasis product being evaluated to control bleeding and fluid loss in order to provide faster and better surgical and interventional care. Arch Therapeutics Initiates Research and Development Collaboration With CURAM Centre for Research in Medical Devices
Marketwired - Mon Jun 01, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, executed a collaboration agreement with CURAM Centre for Research in Medical Devices, a new center of excellence for research based in Galway, Ireland that aims to radically improve health outcomes for patients by developing and collaborating on the development of "smart" medical devices. Arch Therapeutics to Present at 2015 LD MICRO Invitational Conference on June 1
Marketwired - Mon May 18, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, will be featured as a presenting company at the LD MICRO Invitational conference on Monday, June 1, 2015 at 3:30 PM PDT. The conference will be held at the Luxe Sunset Hotel in Bel Air, California. Global Wound Closure Devices Pipeline Review 2015
M2 - Tue Apr 28, 3:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/48sc22/wound_closure) has announced the addition of the "Wound Closure Devices - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key wound closure devices pipeline products. Scope: - Extensive coverage of the Wound Closure Devices products under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Wound Closure Devices and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry The report enables you to: - Formulate significant competitor information, analysis, and insights to improve R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of Wound Closure Devices under development - Develop market-entry and market expansion strategies - Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline - In-depth analysis of the product's current stage of development, territory and estimated launch date Companies Featured: - 3-D Matrix, Ltd. - Advanced Medical Solutions Group plc - Anika Therapeutics, Inc. - Arch Therapeutics Inc. - Arsenal Medical, Inc. - Baxter International Inc. - Bergen Medical Products, Inc. - Beth Israel Deaconess Medical Center, Inc. - Boston Scientific Corporation - Boston University - C. R. Bard, Inc. - Cellphire, Inc. - Clemson University - Emory University - Endomedix Incorporated - Entegrion, Inc. - Floralis S.A.S. - Johns Hopkins University - KeraNetics, LLC - Kitotech Medical, Inc. - Kuros Biosurgery AG - Laser Tissue Welding, Inc. - LifeBond Ltd. - Medical Adhesive Revolution GmbH - Medisse BV - Medtronic plc - OptMed, Inc. - Remedium Technologies Inc. - University of Akron - VitaThreads, LLC - Vivostat A/S - Vivostat A/S - Ongoing Clinical Trials Overview - Xcede Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/48...nd_closure
BSX: 17.60 (+0.15), MDT: 74.37 (+1.28), BAX: 37.61 (+0.59), ANIK: 33.33 (+0.31)
Arch Therapeutics' AC5(TM) Compared Favorably vs. Commercially Available Combination Hemostat in Animal Study
Marketwired - Thu Apr 16, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced that an independent third party has obtained favorable data from an animal study that compared the hemostatic activity of AC5 with a commercially available branded hemostat consisting of a flowable gelatin combined with thrombin. Arch Therapeutics Announces Favorable Preclinical Data From an Independent Study of AC5 Surgical Hemostatic Device(TM) Versus a Popular Fibrin Sealant
Marketwired - Tue Apr 14, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced that an independent third party has obtained favorable data from a preclinical animal study that compared the hemostatic activity of AC5 with a popular and commercially available branded fibrin sealant that is indicated for use in controlling bleeding. Arch Therapeutics Announces Favorable Preclinical Data from an Independent Study of AC5 Surgical Hemostatic Device(TM) Versus a Popular Cellulose-Based Hemostatic Agent
Marketwired - Wed Mar 25, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced that an independent third party has obtained favorable data from a preclinical animal study that compared the hemostatic activity of AC5 with a popular and commercially available branded absorbable hemostatic agent. Arch Therapeutics Announces Positive Safety Results for AC5 Surgical Hemostatic Device(TM) in Preclinical Toxicity Studies
Marketwired - Mon Mar 23, 7:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, obtained additional favorable preclinical data from two (2) planned standardized medical device safety studies in which AC5 was assessed for toxicity to cells and for contamination from pyrogens (toxins that cause fever) produced by bacterial cells. The tests are major components of the panel of biocompatibility testing that medical devices must typically complete successfully prior to use in humans. Nanomedicine: Nanotechnology, Biology, and Medicine Publishes Preclinical Data on Arch Therapeutics' AC5 Surgical Hemostatic Device(TM)
Marketwired - Thu Feb 19, 7:57AM CST
Positive data from an independent third-party research group study sponsored by Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM), was published in the peer-reviewed journal Nanomedicine: Nanotechnology, Biology, and Medicine. The results in the manuscript, titled "AC5 Surgical Hemostat(TM) as an Effective Hemostatic Agent in an Anticoagulated Rat Liver Punch Biopsy Model," show that AC5(TM) is agnostic to the presence of the anticoagulant heparin in animals. The abstract can be accessed online here: http://www.nanomedjournal.com/article/S1549-9...8/abstract. The British Standards Institution Classifies Arch Therapeutics' AC5(TM) as a Medical Device Within the European Union
Marketwired - Tue Feb 17, 7:03AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, a medical device company and developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has received confirmation from The British Standards Institution (BSI), a Notified Body in the European Union (EU), that AC5 fulfills the definition of a medical device within the EU and will be classified as such in consideration for CE mark designation. Eventually obtaining the CE mark for AC5 would allow the Company to sell the product within the EU. Arch Therapeutics Obtains Additional Positive Results for AC5 Surgical Hemostatic Device(TM) in Preclinical Safety Study
Marketwired - Tue Jan 13, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM), obtained positive results when AC5(TM) was subjected to a standardized medical device test for irritation potential. The irritation test in animals is a major component of the International Organization for Standardization's (ISO) required panel of biocompatibility testing necessary for medical devices prior to use in humans. AC5 is a unique development-stage hemostasis product being evaluated to control bleeding and fluid loss in order to provide faster and safer surgical and interventional care. Arch Therapeutics Announces Positive Results for AC5 Surgical Hemostatic Device(TM) in Biochemical and Cell Function Safety Studies
Marketwired - Tue Jan 06, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM), obtained positive results from preclinical tests in which AC5(TM) was subjected to a battery of high-throughput in vitro safety assessments for biological interactions in standardized testing panels of receptors on the surface of cells and protein kinase enzymes inside cells. These receptors and enzymes represent important biochemical "switches," and interactions with them could indicate biological activity with the potential for toxicity. AC5 is a unique development-stage hemostasis product being evaluated to control bleeding and fluid loss in order to provide faster and safer surgical and interventional care. Arch Therapeutics to Present at The Biotech Showcase(TM) 2015 Conference on January 14th 2015
Marketwired - Wed Dec 17, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM), announced that it would be featured as a presenting company at The Biotech Showcase(TM) 2015 Conference on Wednesday, January 14, 2015 at 11:00 AM PST. The conference will be held at the Parc 55 Wyndham Hotel, located at Union Square, San Francisco, California. ARTH Developing Next Generation Biopharma Product in a $5 Billion Market with Plans for Product Launch in 2015
M2 - Wed Dec 10, 7:13AM CST
ARTH's Flagship product AC5(TM) stops bleeding promptly, even in the presence of blood thinners based on animal data to date. Unlike many competitive products, it conforms to irregular wound geometry, allows for normal healing, and helps maintain a clear field of vision.
Arch Therapeutics to Present at LD Micro Main Event on December 4th 2014
Marketwired - Mon Nov 24, 3:00PM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM), announced that it would be featured as a presenting company at the LD Micro conference on Thursday, December 4, 2014 at 12:00 PM EST. The conference will be held at the Luxe Sunset Hotel in Bel Air, California. Arch Therapeutics Reports Positive Preclinical Data from Study of AC5 Surgical Hemostatic Device(TM) in Animals Treated with Brilinta(R) (ticagrelor)
Marketwired - Wed Nov 19, 3:26PM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostat Device(TM), announced that an independent third party has obtained positive data from a preclinical study assessing the use of AC5(TM) in animals that had been treated with orally administered therapeutic doses of the blood thinner ticagrelor, which is currently marketed under the brand name Brilinta(R). The results of the study are consistent with separate data obtained from two recently completed preclinical studies in which AC5 quickly stopped bleeding from surgical wounds created in rats following treatment with clinically relevant doses of the anticoagulant medication heparin; and another preclinical study which reported similar results with respect to the antiplatelet medications Plavix(R) (clopidogrel) and aspirin when used individually and in combination. Anticoagulant and antiplatelet medications are commonly referred to as "blood thinners." Arch Therapeutics Will Present at Two Investor Conferences in November
Marketwired - Mon Nov 10, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM), announced that it would be featured as a presenting company at two conferences in November: SeeThruEquity Microcap Investor Conference and Drexel Hamilton Micro-Cap Investor Forum. 
